JPMorgan assumes coverage on Archer Daniels Midland stock with Neutral rating

Published 20/08/2025, 10:06
JPMorgan assumes coverage on Archer Daniels Midland stock with Neutral rating

Investing.com - JPMorgan has assumed coverage on Archer Daniels Midland (NYSE:ADM), a prominent food products company with a $28.8 billion market cap, with a Neutral rating and a price target of $61.00, up from the previous target of $48.00. According to InvestingPro data, the stock currently trades at $59.96, with analysts’ targets ranging from $48 to $70.

The investment bank expects ADM’s earnings to benefit from improved margins in the Crushing and Nutrition segments over the coming year, potentially exceeding current market estimates, particularly in the Crushing segment.

Despite these positive factors, JPMorgan identifies persistent pressures in the Refined Products and Other segments as offsetting concerns.

The firm also expressed uncertainty about whether the Ag Services segment will rebound to the extent ADM anticipates, especially if U.S. trade tensions do not ease.

While JPMorgan’s earnings per share estimates for ADM exceed the Bloomberg consensus for 2026 and 2027, the firm indicated it does not see sufficient upside potential in the share price to warrant a more positive rating at this time. InvestingPro’s Fair Value analysis suggests the stock is slightly undervalued, with 10+ additional exclusive insights available to subscribers through the comprehensive Pro Research Report.

In other recent news, Archer Daniels Midland (ADM) reported its second-quarter earnings for 2025, achieving an adjusted earnings per share (EPS) of $0.93, which exceeded the forecasted $0.80. However, the company fell short of revenue expectations, posting $21.17 billion compared to the anticipated $21.81 billion. ADM’s Board of Directors declared a quarterly cash dividend of 51 cents per share, marking 93 years of consistent payments. UBS raised its price target for ADM to $70 from $60, maintaining a Buy rating, citing strong crush spread margins and improvements in the nutrition business. UBS also adjusted its earnings per share estimates upward, projecting a 2025 EPS of $3.93. Barclays (LON:BARC) upgraded ADM from Underweight to Equalweight, increasing its price target to $61 from $50, due to enhancements in the Nutrition segment and a recovering crush outlook. The Decatur East plant, which had faced extended downtime, is now back online, eliminating previous cost headwinds. These developments reflect ADM’s ongoing strategic focus on innovation and market optimization.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.